EIREX technology vs Electrolysis in generating hydrogen
DiagnaMed and EIREX Collaborate to Develop and Commercialize Novel Modular Technology Producing Hydrogen from Water
November 14, 2024 08:00 ET | DiagnaMed Holdings Corp.
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI...
Logo_Diagnamed.png
DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement
November 13, 2024 17:45 ET | DiagnaMed Holdings Corp.
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI...
Logo_Diagnamed.png
DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen
November 07, 2024 08:00 ET | DiagnaMed Holdings Corp.
Advancing molecular hydrogen for neurological and mental health disorders Expects its molecular hydrogen product to be ready for use in December 2024 TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) --...
Figure #1
DiagnaMed Advancing the Medical Potential of Hydrogen
October 30, 2024 08:00 ET | DiagnaMed Holdings Corp.
TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on brain health, announces its...
Logo_Diagnamed.png
DiagnaMed Expands with Drug and Clinical Research AI Platform
August 21, 2024 08:00 ET | DiagnaMed Holdings Corp.
Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for...
Logo_Diagnamed.png
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
August 15, 2024 08:00 ET | DiagnaMed Holdings Corp.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...
Logo_Diagnamed.png
DiagnaMed Cancels Previously Announced Private Placement
July 03, 2024 16:00 ET | DiagnaMed Holdings Corp.
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...
Logo_Diagnamed.png
DiagnaMed Announces LIFE Offering of up to $650,000
May 15, 2024 18:10 ET | DiagnaMed Holdings Corp.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...
Opportunity of BRAIN AGE® Brain Health AI Platform
DiagnaMed’s BRAIN AGE® Brain Health AI Platform Targeting Multi-Billion Digital Brain Health Market
May 15, 2024 08:00 ET | DiagnaMed Holdings Corp.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...
DiagnaMed_Logo.jpg
DiagnaMed’s BRAIN AGE® Brain Health AI Platform Accomplishes Clinical Validation Milestone with Peer-Reviewed Paper
April 25, 2024 08:00 ET | DiagnaMed Holdings Corp.
TORONTO, April 25, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...